Brazil ALS Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Brazil · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$20.4 MnPlaceholder estimate
Estimate 2025$22.1 Mn2.4% of the global market
Projected 2034$45.7 Mn 106.7%Adds $23.6 Mn over 9 forecast years
CAGR 2025–20348.4%Faster than 42% of 180 Pharmaceuticals markets here
Key players5
Brazil is 2.41% of the global market.
In Latin America, the largest is Brazil (this report) at $22.1 Mn.
Fastest growing: Brazil (this report) at 8.4% a year.
Brazil ranks 1st of 3 by size in Latin America.
Market size projection
Brazil
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$23.6 Mn total, 2026–2034
Year-by-year market size, 2024–2034
ALS Treatment Market market size by year, Brazil
Year
Market size
Change that year
Since 2025
2024 (estimate)
$20.4 Mn
—
—
2025 (base)
$22.1 Mn
+$1.7 Mn
—
2026 (forecast)
$23.9 Mn
+$1.9 Mn
+8.4%
2027 (forecast)
$26.0 Mn
+$2.0 Mn
+17.5%
2028 (forecast)
$28.1 Mn
+$2.2 Mn
+27.4%
2029 (forecast)
$30.5 Mn
+$2.4 Mn
+38.1%
2030 (forecast)
$33.1 Mn
+$2.6 Mn
+49.7%
2031 (forecast)
$35.8 Mn
+$2.8 Mn
+62.2%
2032 (forecast)
$38.9 Mn
+$3.0 Mn
+75.9%
2033 (forecast)
$42.1 Mn
+$3.3 Mn
+90.6%
2034 (forecast)
$45.7 Mn
+$3.5 Mn
+106.7%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
3 in BrazilSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Brazil ALS Treatment Market Analysis Executive Summary
ALS treatments aim to slow amyotrophic lateral sclerosis, a disease that destroys nerve cells controlling muscles.
Key segments of the ALS Treatment market include drug (Riluzole, Edaravone and Tofersen) and route (Oral, Intravenous and Intrathecal).
Brazil ALS Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Brazil ALS Treatment Market Dynamics
Market Growth Drivers
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the ALS Treatment market.
Opportunity
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the ALS Treatment market strong room to grow.
Market Restraints
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the ALS Treatment market.
Competitive Landscape for ALS Treatment Market in Brazil
The ALS Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for ALS Treatment Market in Brazil
ALS Treatment in Brazil: rules, payment and research
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.[2] ClinicalTrials.gov lists 3 studies on ALS Treatment that are recruiting, active or about to start in Brazil.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ALS Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in ALS Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
ALS Treatment in context
Brazil compared
Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
Placeholder estimate: about $22.1 Mn in 2025, rising to about $45.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the ALS Treatment market in Brazil growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the ALS Treatment market report cover?
The report splits the market by drug (Riluzole, Edaravone, Tofersen, Others), route (Oral, Intravenous, Intrathecal) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the ALS Treatment market?
Key players include Biogen Inc, Mitsubishi Tanabe Pharma Corporation, Amylyx Pharmaceuticals, Sanofi and Cytokinetics.
What is driving the ALS Treatment market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the ALS Treatment market.
Who regulates ALS Treatment in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How many clinical trials on ALS Treatment are running in Brazil?
3 studies are recruiting, active or about to start in Brazil, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Brazil. Retrieved 12 Nov 2026.
How much research is published on ALS Treatment?
PubMed lists 138 papers on ALS Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Brazil 
US
China
Canada
Japan
Germany
France
UK
Ecuador
Italy
Saudi Arabia
India
Spain
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Eli Lilly and Company
Glenmark Pharmaceuticals